Transfusion Needs For Patients With Myelofibrosis In Latin America
Author(s)
Gabriela Abreu, PhD1, Juliana Queiroz, MSc1, Thiago Luiz Nogueira Silva, PhD1, Claudia Soares, PhD, MHP, MD1, Patricia Menezes Rezende, MBA1, Tatiana Pires, PhD1, Straus Tanaka, MSc1, Graziela Bernardino, MBA1, Lucas Perelli, MSc, MD2, Mariano Carrizo, PhD2, Paula Scibona, MD3, Delfina Recart, MD3, Ventura Alejandro Simonovich, MD3, Georgina Bendek Del Prete, MD3, Veronica Privitera, MD3, Fernandes Taís Bertoldo Teixeira, PharmD4, Michel Lima de Moraes, BSc4, Robson Bruniera de Oliveira, PhD4.
1GSK, Rio de Janeiro, Brazil, 2GSK, Buenos Aires, Argentina, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Orizon, São Paulo, Brazil.
1GSK, Rio de Janeiro, Brazil, 2GSK, Buenos Aires, Argentina, 3Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Orizon, São Paulo, Brazil.
OBJECTIVES: Anemia is a defining feature of myelofibrosis (MF), and a considerable number of patients require red blood cell transfusions (RBCTs) as part of their treatment journey. The Hematological Impact in Myelofibrosis in Emerging Markets (HeIIM) real-world study on MF assessed the longitudinal RBCT requirements and transfusion dependency (TD) status in Argentina and Brazil.
METHODS: HeIIM used private insurance medical records data from Argentina (2010-2022) and claims data from Brazil (2015-2022). The study population included patients ≥18 years with ≥1 MF-related record/claim. Index (proxy for MF diagnosis) was the first recorded date of the MF-related record/claim, and patients were followed until death, loss to follow-up, or study end. Time and number of RBC units received were described and patients were classified as having TD if they received ≥2 RBC units in 3 consecutive months during the study period.
RESULTS: In Argentina, 228 patients with MF were included; mean (standard deviation [SD]) age was 68 (14) years. Almost one-third (n=61, 26.8%) required ≥1 RBCT and received a mean of 2.1 units of RBC/year of follow-up. Mean (SD) time of follow-up among patients with transfusions was 50.2 (37.6) months and 78.7% had TD. Mean (SD) time from index to first RBCT was 34.3 (32.8) months. In Brazil, 334 patients with MF were included; mean (SD) age was 62 (19) years. More than two-fifths (n=139, 41.6%) required ≥1 RBCT and received a mean of 12.3 units of RBC/year of follow-up. Mean (SD) time of follow-up among patients with transfusions was 20.4 (18.4) months and 92.8% had TD. Mean (SD) time from index to first RBCT was 3.3 (7.8) months.
CONCLUSIONS: At least one-quarter of patients with MF require RBCT during their treatment, with most classified as having TD. This underscores the need for effective management strategies to mitigate its impact on patient outcomes.
METHODS: HeIIM used private insurance medical records data from Argentina (2010-2022) and claims data from Brazil (2015-2022). The study population included patients ≥18 years with ≥1 MF-related record/claim. Index (proxy for MF diagnosis) was the first recorded date of the MF-related record/claim, and patients were followed until death, loss to follow-up, or study end. Time and number of RBC units received were described and patients were classified as having TD if they received ≥2 RBC units in 3 consecutive months during the study period.
RESULTS: In Argentina, 228 patients with MF were included; mean (standard deviation [SD]) age was 68 (14) years. Almost one-third (n=61, 26.8%) required ≥1 RBCT and received a mean of 2.1 units of RBC/year of follow-up. Mean (SD) time of follow-up among patients with transfusions was 50.2 (37.6) months and 78.7% had TD. Mean (SD) time from index to first RBCT was 34.3 (32.8) months. In Brazil, 334 patients with MF were included; mean (SD) age was 62 (19) years. More than two-fifths (n=139, 41.6%) required ≥1 RBCT and received a mean of 12.3 units of RBC/year of follow-up. Mean (SD) time of follow-up among patients with transfusions was 20.4 (18.4) months and 92.8% had TD. Mean (SD) time from index to first RBCT was 3.3 (7.8) months.
CONCLUSIONS: At least one-quarter of patients with MF require RBCT during their treatment, with most classified as having TD. This underscores the need for effective management strategies to mitigate its impact on patient outcomes.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EPH92
Topic
Epidemiology & Public Health
Topic Subcategory
Disease Classification & Coding
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology